EPIZON Trademark

Trademark Overview

On Tuesday, November 17, 2015, a trademark application was filed for EPIZON with the United States Patent and Trademark Office. The USPTO has given the EPIZON trademark a serial number of 86822653. The federal status of this trademark filing is REGISTERED as of Tuesday, February 18, 2020. This trademark is owned by Epizon Pharma, Inc.. The EPIZON trademark is filed in the Computer & Software Services & Scientific Services category with the following description:

development of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reactions, anaphylaxis or asthma
epizon

General Information

Serial Number86822653
Word MarkEPIZON
Filing DateTuesday, November 17, 2015
Status700 - REGISTERED
Status DateTuesday, February 18, 2020
Registration Number5991378
Registration DateTuesday, February 18, 2020
Mark Drawing3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, November 1, 2016

Trademark Statements

Description of MarkThe mark consists of the word "EPIZON" featuring a benzene ring as the "O".
Indication of Colors claimedColor is not claimed as a feature of the mark.
Goods and Servicesdevelopment of pharmaceutical preparations and medicines; pharmaceutical products development; pharmaceutical research and development; research and development in the pharmaceutical and biotechnology fields; research in the field of pharmaceuticals and drugs, excluding devices or drug systems for the delivery of pharmaceuticals for the treatment of allergic reactions, anaphylaxis, or asthma and pharmaceuticals for the treatment of allergic reactions, anaphylaxis or asthma

Classification Information

International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateFriday, November 20, 2015
Primary Code042
First Use Anywhere DateMonday, December 23, 2019
First Use In Commerce DateMonday, December 23, 2019

Trademark Owner History

Party NameEpizon Pharma, Inc.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressWoodbridge, CT 06525
Party NameEpizon Pharma, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressWoodbridge, CT 06525
Party NameEpizon Pharma, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressWoodbridge, CT 06525

Trademark Events

Event DateEvent Description
Thursday, August 25, 2016ASSIGNED TO LIE
Friday, November 20, 2015NEW APPLICATION ENTERED
Friday, November 20, 2015NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Saturday, November 21, 2015NOTICE OF DESIGN SEARCH CODE E-MAILED
Wednesday, March 9, 2016ASSIGNED TO EXAMINER
Friday, March 11, 2016NON-FINAL ACTION WRITTEN
Friday, March 11, 2016NON-FINAL ACTION E-MAILED
Friday, March 11, 2016NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, August 19, 2016TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, September 1, 2016CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, September 1, 2016TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 27, 2016NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Monday, May 1, 2017CASE ASSIGNED TO INTENT TO USE PARALEGAL
Tuesday, September 20, 2016APPROVED FOR PUB - PRINCIPAL REGISTER
Monday, September 26, 2016LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, October 12, 2016NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, November 1, 2016PUBLISHED FOR OPPOSITION
Tuesday, November 1, 2016OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, April 11, 2017TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Friday, June 2, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, November 29, 2017NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, May 5, 2017APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Wednesday, May 31, 2017TEAS CHANGE OF CORRESPONDENCE RECEIVED
Wednesday, May 31, 2017SOU TEAS EXTENSION RECEIVED
Wednesday, May 31, 2017SOU EXTENSION 1 FILED
Wednesday, May 31, 2017SOU EXTENSION 1 GRANTED
Monday, November 27, 2017SOU TEAS EXTENSION RECEIVED
Monday, November 27, 2017SOU EXTENSION 2 FILED
Monday, November 27, 2017SOU EXTENSION 2 GRANTED
Thursday, January 3, 2019DIVISIONAL PROCESSING COMPLETE
Friday, May 25, 2018SOU TEAS EXTENSION RECEIVED
Friday, May 25, 2018SOU EXTENSION 3 FILED
Friday, May 25, 2018SOU EXTENSION 3 GRANTED
Tuesday, May 29, 2018NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, November 29, 2018TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Wednesday, December 19, 2018SOU TEAS EXTENSION RECEIVED
Wednesday, December 19, 2018TEAS REQUEST TO DIVIDE RECEIVED
Wednesday, December 19, 2018DIVISIONAL REQUEST RECEIVED
Wednesday, December 19, 2018SOU EXTENSION 4 FILED
Thursday, January 3, 2019SOU EXTENSION 4 GRANTED
Thursday, December 26, 2019TEAS STATEMENT OF USE RECEIVED
Thursday, December 26, 2019USE AMENDMENT FILED
Friday, January 4, 2019CORRECTED NOA E-MAILED
Friday, January 4, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Wednesday, June 26, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, June 26, 2019SOU EXTENSION 5 FILED
Monday, July 8, 2019SOU EXTENSION 5 GRANTED
Tuesday, July 9, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Saturday, December 28, 2019STATEMENT OF USE PROCESSING COMPLETE
Friday, January 17, 2020NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
Tuesday, February 18, 2020REGISTERED-PRINCIPAL REGISTER
Tuesday, February 18, 2025COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Thursday, January 16, 2020ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED

Related Keywords

epizon development pharmaceutical pharmaceuticals research anaphylaxis asthma reactions treatment allergic systems